The authors analyze the critical points and the results of the paper OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer,published by Aghajanian C et al on 10 june 2012 in J Clin Oncol

Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View / Tomao, Federica; Tomao, Silverio; Panici, P. B.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:1(2013), pp. 166-167. [10.1200/jco.2012.44.6237]

Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View

TOMAO, FEDERICA;TOMAO, SILVERIO;P. B. Panici
2013

Abstract

The authors analyze the critical points and the results of the paper OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer,published by Aghajanian C et al on 10 june 2012 in J Clin Oncol
2013
ovarian cancer; bevacizumab; survival
01 Pubblicazione su rivista::01b Commento, Erratum, Replica e simili
Improvement in Progression-Free Survival in OCEANS Bevacizumab Arm: A Critical Point of View / Tomao, Federica; Tomao, Silverio; Panici, P. B.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 31:1(2013), pp. 166-167. [10.1200/jco.2012.44.6237]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/511814
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact